Search

Your search keyword '"Eisen, Howard J."' showing total 565 results
Start Over Author "Eisen, Howard J."
565 results on '"Eisen, Howard J."'

151. Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study)

Author

Phillips, Michael, primary, Boehmer, John P, additional, Cataneo, Renee N, additional, Cheema, Taseer, additional, Eisen, Howard J, additional, Fallon, John T, additional, Fisher, Peter E, additional, Gass, Alan, additional, Greenberg, Joel, additional, Kobashigawa, Jon, additional, Mancini, Donna, additional, Rayburn, Barry, additional, and Zucker, Mark J, additional

Published
2004
Full Text
View/download PDF

153. Conceptual development of the DESDynI mission.

Author

Eisen, Howard J., Jai, Ben, Rosen, Paul A., Veilleux, Louise, and Xaypraseuth, Peter

Abstract

The high value of Radar and Lidar data for understanding climate change and earth dynamics led to the prioritization of the Deformation, Ecosystem Structure and Dynamics of Ice (DESDynI) mission as Tier One in the last National Academy of Sciences' Earth Science Decadal Survey. A mission concept that matched those desired objectives underwent pre-Project development and passed several layers of review in late 2010 and early 2011 with the target of a 2017 launch. However, cuts in the proposed FY2012 budget forced a reset of the Radar mission and eliminated the Lidar sciencecraft. The proposed DESDynI-Radar mission may now fulfill a more limited set of objectives with a more modest budget on a longer development timescale. A multitude of options have been studied with varying levels of cost, risk and science value. Flight and Ground system implementations have a direct bearing on many of these factors and will also be addressed. The methodology and status of evaluating these options will be discussed. A key distinguishing characteristic of the projected DESDynI-Radar measurement would be large scale coverage and frequent revisit at fine resolution. This would be enabled via a new Radar technique called SweepSAR. Efforts to develop and field test SweepSAR will also be discussed, as well as other technology developments underway that are associated with this mission. [ABSTRACT FROM PUBLISHER]

Published
2012
Full Text
View/download PDF

162. Management of Hypertension in Patients With Ventricular Assist Devices: A Scientific Statement From the American Heart Association.

Author

Eisen, Howard J., Flack, John M., Atluri, Pavan, Bansal, Neha, Breathett, Khadijah, Brown, Angela L., Hankins, Shelley R., Khazanie, Prateeti, Masri, Carolina, Pirlamarla, Preethi, and Rowe, Theresa

Abstract

Mechanical circulatory support with durable continuous-flow ventricular assist devices has become an important therapeutic management strategy for patients with advanced heart failure. As more patients have received these devices and the duration of support per patient has increased, the postimplantation complications have become more apparent, and the need for approaches to manage these complications has become more compelling. Continuous-flow ventricular assist devices, including axial-flow and centrifugal-flow pumps, are the most commonly used mechanical circulatory support devices. Continuous-flow ventricular assist devices and the native heart have a constant physiological interplay dependent on pump speed that affects pressure-flow relationships and patient hemodynamics. A major postimplantation complication is cerebrovascular vascular accidents. The causes of cerebrovascular vascular accidents in ventricular assist device recipients may be related to hypertension, thromboembolic events, bleeding from anticoagulation, or some combination of these. The most readily identifiable and preventable cause is hypertension. Hypertension management in these patients has been hampered by the fact that it is difficult to accurately measure blood pressure because these ventricular assist devices have continuous flow and are often not pulsatile. Mean arterial pressures have to be identified by Doppler or oscillometric cuff and treated. Although guidelines for hypertension management after ventricular assist device implantation are based largely on expert consensus and conventional wisdom, the mainstay of treatment for hypertension includes guideline-directed medical therapy for heart failure with reduced ejection fraction because this may reduce adverse effects associated with hypertension and increase the likelihood of favorable ventricular remodeling. The use of systemic anticoagulation in ventricular assist device recipients may at a given blood pressure increase the risk of stroke. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

164. SAFETY, TOLERABILITY, AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL-BASED FORMULATION OF CYCLOSPORINE???RESULTS AT 24 MONTHS AFTER TRANSPLANTATION1

Author

Eisen, Howard J., primary, Hobbs, Robert E., additional, Davis, Stacy F., additional, Carrier, Michel, additional, Mancini, Donna M., additional, Smith, Andrew, additional, Valantine, Hannah, additional, Ventura, Hector, additional, Mehra, Mandeep, additional, Vachiery, Jean-Luc, additional, Rayburn, Barry K., additional, Canver, Charles C., additional, Laufer, Guenther, additional, Costanzo, Maria-Rosa, additional, Copeland, Jack, additional, Dureau, Georges, additional, Frazier, O. Howard, additional, Dorent, Richard, additional, Hauptman, Paul J., additional, Kells, Catherine, additional, Masters, Roy, additional, Michaud, Jean-Luc, additional, Paradis, Irvin, additional, Renlund, Dale G., additional, Vanhaecke, Johan, additional, Mellein, Bernhard, additional, and Mueller, Edgar A., additional

Published
2001
Full Text
View/download PDF

170. SAFETY, TOLERABILITY AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL BASED FORMULATION OF CYCLOSPORINE - RESULTS AT SIX MONTHS AFTER TRANSPLANTATION1,2

Author

Eisen, Howard J., primary, Hobbs, Robert E., additional, Davis, Stacy F., additional, Laufer, Guenther, additional, Mancini, Donna M., additional, Renlund, Dale G., additional, Valantine, Hannah, additional, Ventura, Hector, additional, Vachiery, Jean-Luc, additional, Bourge, Robert C., additional, Canver, Charles C., additional, Carrier, Michel, additional, Costanzo, Maria-Rosa, additional, Copeland, Jack, additional, Dureau, Georges, additional, Frazier, O. Howard, additional, Dorent, Richard, additional, Hauptman, Paul J., additional, Kells, Catherine, additional, Masters, Roy, additional, Michaud, Jean-Luc, additional, Paradis, Irvin, additional, Smith, Andrew, additional, Vanhaecke, Johan, additional, Feutren, Gilles, additional, Turkin, Diane, additional, Mellein, Bernd, additional, and Mueller, Edgar A., additional

Published
1999
Full Text
View/download PDF

172. Soil-like deposits observed by Sojourner, the Pathfinder rover

Author

Moore, Henry J., primary, Bickler, Donald B., additional, Crisp, Joy A., additional, Eisen, Howard J., additional, Gensler, Jeffrey A., additional, Haldemann, Albert F. C., additional, Matijevic, Jacob R., additional, Reid, Lisa K., additional, and Pavlics, Ferenc, additional

Published
1999
Full Text
View/download PDF

182. Raman Spectroscopy Detects Cardiac Allograft Rejection with Molecular Specificity.

Author

Yoon Gi Chung, Qiang Tu, Dianjun Cao, Shuko Harada, Eisen, Howard J., and Chang Chang

Subjects
RAMAN spectroscopy, HEART transplantation, SEROTONIN, BIOMARKERS, IMMUNE response, BIOPSY, MEDICAL care
Abstract

Spatially resolved Raman spectroscopy is shown here to be capable of molecular-specific detection without exogenous labeling. This molecular specificity is achieved by detecting the strong and characteristic Raman spectral signature of an indole derivative, serotonin, whose selective existence in rejected heart transplants serves as the biomarker. The study also corroborates the increasingly recognized role of serotonin receptors in various immune responses, including cardiac allograft rejection. Combining both medical and physical sciences, this work demonstrates the potential use of Raman spectroscopy in replacing the invasive endomyocardial biopsy as the standard for post-transplantation rejection surveillance and presents a new paradigm in advancing clinical care through interdisciplinary studies. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

183. Surgical Ventricular Reconstruction for Heart Failure.

Author

Eisen, Howard J.

Subjects
*CLINICAL trials, *CORONARY artery bypass, *HEART failure treatment, *VENTRICULAR remodeling, RESEARCH evaluation
Abstract

The author comments on the report by Jones et al. that examines the results of the Hypothesis 2 substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. The trial compared medical therapy plus coronary-artery bypass grafting (CABG) with medical therapy alone. He believes that the routine use of surgical ventricular reconstruction in addition to CABG cannot be justified based on the trial.

Published
2009
Full Text
View/download PDF

186. SAFETY, TOLERABILITY, AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL-BASED FORMULATION OF CYCLOSPORINE—RESULTS AT 24 MONTHS AFTER TRANSPLANTATION1

Author

Eisen, Howard J., Hobbs, Robert E., Davis, Stacy F., Carrier, Michel, Mancini, Donna M., Smith, Andrew, Valantine, Hannah, Ventura, Hector, Mehra, Mandeep, Vachiery, Jean-Luc, Rayburn, Barry K., Canver, Charles C., Laufer, Guenther, Costanzo, Maria-Rosa, Copeland, Jack, Dureau, Georges, Frazier, O. Howard, Dorent, Richard, Hauptman, Paul J., and Kells, Catherine

Published
2001
Full Text
View/download PDF

194. mTOR inhibitors vs calcineurin inhibitors: A Catch-22—preventing nephrotoxicity or acute allograft rejection after heart transplantation

Author

Tsay, Annie J. and Eisen, Howard J.

Abstract

The authors capture the historical importance of the MANDELA trial and its unique study design, which examines two renal-sparing strategies, not including a standard calcineurin inhibitor arm, after heart transplant to illustrate the ongoing challenge of balancing acute rejection and drug-induced nephrotoxicity. See the original article from Barten et al on page 3006.

Published
2019
Full Text
View/download PDF

195. mTORinhibitors vs calcineurin inhibitors: A Catch‐22—preventing nephrotoxicity or acute allograft rejection after heart transplantation

Author

Tsay, Annie J. and Eisen, Howard J.

Abstract

The authors capture the historical importance of the MANDELA trial and its unique study design, which examines two renal‐sparing strategies, not including a standard calcineurin inhibitor arm, after heart transplant to illustrate the ongoing challenge of balancing acute rejection and drug‐induced nephrotoxicity. See the original article from Barten et al on page 3006.

Published
2019
Full Text
View/download PDF

196. Brief Communication The Economic Implications of Noninvasive Molecular Testing for Cardiac Allograft Rejection

Author

Evans, Roger W., Williams, Gavin E., Baron, Helen M., Deng, Mario C., Eisen, Howard J., Hunt, Sharon A., Khan, Mahmud M., Kobashigawa, Jon A., Marton, Eric N., Mehra, Mandeep R., and Mital, Seema R.

Abstract

Endomyocardial biopsy is the mainstay for monitoring cardiac allograft rejection. A noninvasive strategy—peripheral blood gene expression profiling of circulating leukocytes—is an alternative with proven benefits, but unclear economic implications. Financial data were obtained from five cardiac transplant centers. An economic evaluation was conducted to compare the costs of outpatient biopsy with those of a noninvasive approach to monitoring cardiac allograft rejection. Hospital outpatient biopsy costs averaged $3297, excluding reimbursement for professional fees. Costs to Medicare and private payers averaged $3581 and $4140, respectively. A noninvasive monitoring test can reduce biopsy utilization. The savings to health care payers in the United States can be conservatively estimated at approximately $12.0 million annually. Molecular testing using gene expression profiling of peripheral circulating leukocytes is a new technology that offers physicians a noninvasive, less expensive alternative to endomyocardial biopsy for monitoring allograft rejection in cardiac transplant patients.

Published
2005
Full Text
View/download PDF

197. The Economic Implications of Noninvasive Molecular Testing for Cardiac Allograft Rejection

Author

Evans, Roger W., Williams, Gavin E., Baron, Helen M., Deng, Mario C, Eisen, Howard J., Hunt, Sharon A., Khan, Mahmud M, Kobashigawa, Jon A., Marton, Eric N., Mehra, Mandeep R., and Mital, Seema R.

Abstract

Endomyocardial biopsy is the mainstay for monitoring cardiac allograft rejection. A noninvasive strategy— peripheral blood gene expression profiling of circulating leukocytes— is an alternative with proven benefits, but unclear economic implications. Financial data were obtained from five cardiac transplant centers. An economic evaluation was conducted to compare the costs of outpatient biopsy with those of a noninvasive approach to monitoring cardiac allograft rejection. Hospital outpatient biopsy costs averaged $3297, excluding reimbursement for professional fees. Costs to Medicare and private payers averaged $3581 and $4140, respectively. A noninvasive monitoring test can reduce biopsy utilization. The savings to health care payers in the United States can be conservatively estimated at approximately $12.0 million annually. Molecular testing using gene expression profiling of peripheral circulating leukocytes is a new technology that offers physicians a noninvasive, less expensive alternative to endomyocardial biopsy for monitoring allograft rejection in cardiac transplant patients.

Published
2005
Full Text
View/download PDF

198. Feasibility of photopheresis to reduce the occurrence of restenosis after percutaneous transluminal coronary angioplasty: A clinical pilot study

Author

Bisaccia, Emil, Klainer, Albert S., Gonzalez, Joselyn, Schwartz, Joseph, Randazzo, Domenick, Antonucci, Lawrence C., Shioleno, Charles A., Eisen, Howard J., and Banas, John S.

Abstract

BackgroundPhotopheresis was evaluated as a means of preventing restenosis on the basis of immune modulation. MethodsThis was a prospective, randomized, controlled clinical trial analyzing clinical restenosis at 6 months after percutaneous transluminal coronary angioplasty (PTCA). Seventy-eight patients with single-vessel angioplasty were randomly assigned to a control group of 41 patients and a treatment group of 37 patients. At 6 months, there were 72 evaluable patients: 39 control patients and 33 treated. Twenty-nine control patients received balloon PTCA only and 10 patients received stents. Twenty treated patients received PTCA only and 13 patients received stents. Baseline clinical characteristics of both groups were similar. The treatment group received photopheresis for a total of 5 treatments. Primary end points were death from any cause, myocardial infarction, ischemia, and repeat revascularization procedures. ResultsBy intention-to-treat analysis, clinical restenosis occurred in 27% of control patients versus 8% of treated patients (P=.040, relative risk = 0.30). ConclusionsPhotopheresis therapy in patients undergoing balloon PTCA with and without stent deployment has been shown to be effective in reducing restenosis. The use of photopheresis in such patients merits further investigation. (Am Heart J 2001;142:461-5.)

Published
2001
Full Text
View/download PDF

199. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans Histological analysis of cell survival and differentiation

Author

Pagani, Francis D, DerSimonian, Harout, Zawadzka, Agatha, Wetzel, Kristie, Edge, Albert S.B, Jacoby, Douglas B, Dinsmore, Jonathan H, Wright, Susan, Aretz, Tom H, Eisen, Howard J, and Aaronson, Keith D

Abstract

ObjectivesWe report histological analysis of hearts from patients with end-stage heart disease who were transplanted with autologous skeletal myoblasts concurrent with left ventricular assist device (LVAD) implantation.BackgroundAutologous skeletal myoblast transplantation is under investigation as a means to repair infarcted myocardium. To date, there is only indirect evidence to suggest survival of skeletal muscle in humans.MethodsFive patients (all male; median age 60 years) with ischemic cardiomyopathy, refractory heart failure, and listed for heart transplantation underwent muscle biopsy from the quadriceps muscle. The muscle specimen was shipped to a cell isolation facility where myoblasts were isolated and grown. Patients received a transplant of 300 million cells concomitant with LVAD implantation. Four patients underwent LVAD explant after 68, 91, 141, and 191 days of LVAD support (three transplant, one LVAD death), respectively. One patient remains alive on LVAD support awaiting heart transplantation.ResultsSkeletal muscle cell survival and differentiation into mature myofibers were directly demonstrated in scarred myocardium from three of the four explanted hearts using an antibody against skeletal muscle-specific myosin heavy chain. An increase in small vessel formation was observed in one of three patients at the site of surviving myotubes, but not in adjacent tissue devoid of engrafted cells.ConclusionsThese findings represent demonstration of autologous myoblast cell survival in human heart. The implanted skeletal myoblasts formed viable grafts in heavily scarred human myocardial tissue. These results establish the feasibility of myoblast transplants for myocardial repair in humans.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results